Risk factors for developing pacing induced LV dysfunction: Experience from a tertiary center in the UK.
Atrial Fibrillation
/ therapy
Cardiac Pacing, Artificial
/ methods
Cardiac Resynchronization Therapy
/ adverse effects
Female
Heart Failure
/ therapy
Humans
Male
Retrospective Studies
Risk Factors
Stroke Volume
Treatment Outcome
United Kingdom
/ epidemiology
Ventricular Dysfunction, Left
Ventricular Function, Left
heart failure
left ventricular dysfunction
pacemaker
pacing induced left ventricular dysfunction
right ventricular pacing
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
04
12
2021
received:
03
10
2021
accepted:
02
01
2022
pubmed:
14
1
2022
medline:
22
4
2022
entrez:
13
1
2022
Statut:
ppublish
Résumé
The risk factors for developing pacing induced left ventricular dysfunction (LVD) in patients with high burden of right ventricular pacing (RVP) is poorly understood. Therefore, in the present study, we aimed to assess the determinants of pacing induced LVD. Our data were retrospectively collected from 146 patients with RVP > 40% who underwent generator change (GC) or cardiac resynchronization therapy (CRT) upgrade between 2016 and 2019 who had left ventricular ejection fraction (EF) ≥50% at initial implant. A total of 75 patients had CRT upgrade due to pacing induced LVD (EF < 50%) and 71 patients with preserved LV function (EF ≥ 50%) had a GC. Primary indication for pacing in both groups was complete heart block. Male predominance (p = .008), prior myocardial infarction (MI) (p = .001), atrial fibrillation (AF) (p = .009), chronic kidney disease (CKD) (p = .005), and borderline low systolic function (BLSF) (EF 50%-55%) (p = .04) were more prevalent in the CRT upgrade group. Presence of AF (odds ratio [OR] = 3.05, 95% confidence interval [CI] 1.42-6.58; p = .004), BLSF (OR = 3.8, 95% CI 1.22-11.8; p = .02), and male gender (OR = 2.41, 95% CI 1.14-5.08; p = .02) were independent predictors for RVP induced LVD. Age (OR = 1.08, 95% CI 1.02-1.14; p = .005) and BLSF (OR = 5.33, 95% CI 1.26-22.5; p = .023) were independent predictors of earlier development of LVD after implant. Our results suggested that AF, BLSF, and male gender are predictors for development of pacing induced LVD in patients with high RVP burden. LVD can occur at any time after pacemaker implant with BLSF and increasing age associated with earlier development of LVD.
Sections du résumé
BACKGROUND
BACKGROUND
The risk factors for developing pacing induced left ventricular dysfunction (LVD) in patients with high burden of right ventricular pacing (RVP) is poorly understood. Therefore, in the present study, we aimed to assess the determinants of pacing induced LVD.
METHODS
METHODS
Our data were retrospectively collected from 146 patients with RVP > 40% who underwent generator change (GC) or cardiac resynchronization therapy (CRT) upgrade between 2016 and 2019 who had left ventricular ejection fraction (EF) ≥50% at initial implant.
RESULTS
RESULTS
A total of 75 patients had CRT upgrade due to pacing induced LVD (EF < 50%) and 71 patients with preserved LV function (EF ≥ 50%) had a GC. Primary indication for pacing in both groups was complete heart block. Male predominance (p = .008), prior myocardial infarction (MI) (p = .001), atrial fibrillation (AF) (p = .009), chronic kidney disease (CKD) (p = .005), and borderline low systolic function (BLSF) (EF 50%-55%) (p = .04) were more prevalent in the CRT upgrade group. Presence of AF (odds ratio [OR] = 3.05, 95% confidence interval [CI] 1.42-6.58; p = .004), BLSF (OR = 3.8, 95% CI 1.22-11.8; p = .02), and male gender (OR = 2.41, 95% CI 1.14-5.08; p = .02) were independent predictors for RVP induced LVD. Age (OR = 1.08, 95% CI 1.02-1.14; p = .005) and BLSF (OR = 5.33, 95% CI 1.26-22.5; p = .023) were independent predictors of earlier development of LVD after implant.
CONCLUSIONS
CONCLUSIONS
Our results suggested that AF, BLSF, and male gender are predictors for development of pacing induced LVD in patients with high RVP burden. LVD can occur at any time after pacemaker implant with BLSF and increasing age associated with earlier development of LVD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-373Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverterdefibrillators calendar year 2009-a World Society of Arrhythmia's project. Pacing Clin Electrophysiol. 2011;34:1013-1027.
Tops LF, Schalij MJ, Bax JJ. The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. J Am Coll Cardiol. 2009;54:764-776.
Bank AJ, Gage RM, Burns KV. Right ventricular pacing, mechanical dyssynchrony, and heart failure. J Cardiovasc Transl Res. 2012;5:219-231.
Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014;11:1619-1625.
Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005;2:830-834.
Cho SW, Gwag HB, Hwang JK, et al. Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. Eur J Heart Fail. 2019;21:643-651.
Kim JH, Kang KW, Chin JY, Kim TS, Park JH, Choi YJ. Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block: a multicentre, retrospective analysis over a 15-year period in South Korea. BMJ Open. 2018;8:e019048.
Tayal B, Fruelund P, Sogaard P, et al. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study. Eur Heart J. 2019;40:3641-3648.
Khurshid S, Liang JJ, Owens A, et al. Longer paced QRS duration is associated with increased prevalence of right ventricular pacing-induced cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:1174-1179.
Mazza A, Bendini MG, Leggio M, et al. Incidence and predictors of heart failure hospitalization and death in permanent pacemaker patients: a single-centre experience over medium-term follow-up. Europace. 2013;15:1267-1272.
Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and clinical outcomes of pacing induced cardiomyopathy in patients with normal left ventricular systolic function and atrioventricular block. Am J Cardiol. 2020;128:174-180.
Merchant FM, Mittal S. Pacing induced cardiomyopathy. J Cardiovasc Electrophysiol. 2020;31:286-292.
Lee SA, Cha MJ, Cho Y, Oh IY, Choi EK, Oh S. Paced QRS duration and myocardial scar amount: predictors of long-term outcome of right ventricular apical pacing. Heart Vessels. 2016;31:1131-1139.
Merchant FM, Hoskins MH, Musat DL, et al. Incidence and time course for developing heart failure with high-burden right ventricular pacing. Circ Cardiovasc Qual Outcomes. 2017;10:e003564.
Harkness A, Ring L, Augustine DX, et al. Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography. Echo Res Pract. 2020;7:G1-G18. https://doi.org/10.1530/ERP-19-0050.
Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.
Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2016;13:131-147.
Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610-623. https://doi.org/10.1038/nrneph.2016.113.
Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2022;24:71-164. https://doi.org/10.1093/europace/euab232.
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;140:e382-e482. https://doi.org/10.1161/CIR.0000000000000628.